SPOTLIGHT: Vasella defends dual role at Novartis

Novartis Chairman and CEO Daniel Vasella (photo) got a bit defensive at his company's annual meeting yesterday. Questioned about his pulling double duty as chairman and CEO, Vasella countered that firms with one person in each slot spend too much time and money settling conflicts between the two. Report

Suggested Articles

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.

In its quest to become the dominant SGLT2 diabetes med for heart failure, Jardiance is touting DPP-4 inhibitor-topping data to support its case.

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.